VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MDS 2021 | Novel strategies for treating cytopenia in MDS

Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses novel treatments for cytopenia in myelodysplastic syndromes (MDS) at ESH MDS 2021. In particular, he highlights anti-inflammatory treatments in the early stages of development and a Phase II/III trial (NCT02598661) evaluating imetelstat in patients with low- or intermediate-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter